How does TB-500 differ from Thymosin Beta-4?

TB-500 is essentially a synthetic version of Thymosin Beta-4. The terms are often used interchangeably in research contexts. Both refer to the same 43-amino acid sequence with identical biological activity.

What is a typical TB-500 research protocol?

Research protocols commonly involve a 'loading' phase with higher initial dosing frequency, followed by a 'maintenance' phase. Specific protocols vary based on the research application and model system used.

Can TB-500 be combined with other peptides?

TB-500 is frequently studied in combination with BPC-157 in research settings. The two peptides have different mechanisms of action and are believed to have potentially complementary effects in cellular pathway studies.

How long is TB-500 stable once reconstituted?

Reconstituted TB-500 is stable for approximately 2-3 weeks when stored properly at 2-8°C. For longer storage, aliquoting and freezing at -20°C is recommended.

29 sold in the last 24 hours

Order in 0h 0min for same-day shipping

99.85% Purity Verified

Third-Party Tested by Verum Analytics• HPLC-UV/MS

Batch: BIL-BATCH-01-2602Mar 2, 2026

Synthetic Peptide Compounds

TB-500

Name: TB-500
Brand: BioInfinity
SKU: tb-500
Availability: InStock
Rating: 5.0 (1 reviews)

Thymosin Beta-4 fragment — systemic tissue repair, cell migration, and full-body recovery peptide.

$55.00

99.85% Purity Verified

Third-Party Tested by Verum Analytics• HPLC-UV/MS

Batch: BIL-BATCH-01-2602Mar 2, 2026

+99% Purity

Third-Party Tested

COA Available

29 sold in the last 24 hours

Order in 0h 0min for same-day shipping

Select Size

Buy More, Save More

QuantityPrice

Quantity

Add 2 more for 15% off

$55.00

Albert's Verdict

Thymosin Beta-4's actin-binding mechanism is what makes it exceptional — it drives how tissue reorganizes in wound-model research. The migration data on endothelial cells is some of the most consistent I've reviewed.

View COA

✓ In stock - Ships same day

Arrives as lyophilized (powder) form

Shipped freeze-dried for maximum stability and shelf life. See laboratory preparation guide for handling instructions.

Secure Checkout256-bit SSL

Same-Day DispatchOrder by 2PM EST

Free ShippingOn orders over $200

99%+ Purity3rd-party HPLC

Sterility & EndotoxinsPASSED — every lot

Money-Back Guarantee30-day return window

Researchers also added

Research profile

Thymosin β4-derived actin-sequestering peptide

A 43-residue peptide (or its Ac-SDKP N-terminal tetrapeptide fragment) characterised as a G-actin-sequestering molecule with published effects on cytoskeletal dynamics and vascular remodelling in preclinical models. For laboratory characterisation only.

NonpolarPolarPositiveNegativeAromaticCys

43-residue schematic

Molecular formula

C212H350N56O78S

Molecular weight

4964 g/mol (full Tβ4)

Sequence length

43 residues

Physical form

Lyophilized powder

Documented purity

≥99% (HPLC)

Research use onlyPubChem CID 3037653 ↗

Mechanism of action

Receptor engagement in the primary literature

Binding and functional-assay data for TB-500, from peer-reviewed in-vitro pharmacology publications. Values are receptor activity parameters — not clinical outcomes.

G-actin

Monomeric G-actin

Sequesterer (in vitro)

Thymosin β4 is characterised in the primary literature as the principal G-actin-sequestering peptide in mammalian cells, maintaining the monomeric actin pool.

Source: Goldstein et al., Nat Rev Mol Cell Biol 2005

VEGF

VEGF axis

Upregulation (in vitro)

In-vitro endothelial and myocardial models report Tβ4-mediated upregulation of vascular endothelial growth factor, proposed as an angiogenic mechanism.

Source: Bock-Marquette et al., Nature 2004

MMP

Matrix metalloproteinases 2/9

Modulator (in vitro)

Corneal-wound and dermal in-vitro assays describe Tβ4-mediated modulation of MMP-2 and MMP-9, implicated in extracellular matrix remodelling.

Source: Sosne et al., Ann N Y Acad Sci 2010

Receptor EC₅₀ values from in-vitro cAMP functional assays reported in peer-reviewed literature. In-vitro / preclinical characterisation only — no clinical or therapeutic claim is expressed or implied. Research use only.

Study framework

Investigational context

Study designs referencing this compound in the published literature. Descriptions cover framework only — phase, participant count, duration, and citation — not outcomes. Click a card to review the source directly.

Cardiac repair model

In-vitro + murine post-MI cardiomyocyte assays

Bock-Marquette et al., Nature 2004

Corneal-wound model

Rabbit corneal epithelial healing assays

Sosne et al., Exp Eye Res 2002

Structural review

G-actin sequestration mechanism review

Goldstein et al., Nat Rev 2005

Independent COA

≥99% purity · <0.05 EU/mL endotoxin · lot-specific

Freedom Diagnostic (accredited)

Compound comparison

Chemistry comparison — regenerative research peptides

Two peptides frequently studied together in tissue-regeneration research. Reference chemistry only — no comparative-effectiveness claim expressed or implied.

Compound	Sequence	MW	Half-life (lit.)	Reference
BPC-157 peptide	15 residues	1419.53 g/mol	in-vitro dependent	Sikiric 2018 review
Thymosin β4 (TB-500 fragment) peptide	43 residues (full-length Tβ4)	4964 g/mol (Tβ4)	in-vitro dependent	Goldstein Nat Rev 2005

Reference chemistry only. Receptor-binding indications are qualitative (compound engages / does not engage the receptor in in-vitro assays as reported in the cited literature). No comparative-effectiveness claim is expressed or implied.

Cited sources

Peer-reviewed literature

Independent published research indexed from PubMed and peer-reviewed journals — not BioInfinity claims.

[1]PubMed

Thymosin beta 4 and cardiac protection: implication in inflammation and fibrosis

2012 · Ann N Y Acad Sci

View source

[2]PubMed

Thymosin beta-4: a multi-functional regenerative peptide

2007 · Expert Opin Biol Ther

View source

[3]PubMed

Thymosin beta-4 and the anti-fibrotic effects on the heart

2010 · Ann N Y Acad Sci

View source

For research use only.

Not for human or veterinary use. All data on this page reflects chemistry attributes, in-vitro pharmacology, and study-framework metadata from published peer-reviewed literature. No statement describes or implies any therapeutic effect in humans. These statements have not been evaluated by the FDA; this product is not intended to diagnose, treat, cure, or prevent any disease. Sold exclusively to qualified researchers and institutions.

Product Description

What TB-500 (Thymosin Beta-4 Fragment) is

TB-500 (Thymosin Beta-4 Fragment) is a synthetic heptapeptide fragment of thymosin beta-4. TB-500 is a synthetic 7-amino-acid fragment from thymosin beta-4's actin-binding site. A Phase 1/2 trial launched February 2026 investigates its cardiovascular effects in adults with stable atherosclerotic disease. Phase 1 safety data in 84 healthy volunteers showed favorable tolerability. 2025 research reveals its wound-healing activity may stem from the metabolite Ac-LKKTE rather than the parent compound. It has a molecular formula C212H350N56O78S (full Tβ4), mass 4963 Da (full Tβ4) / ~900 Da (TB-500 fragment) Da. Its published amino-acid sequence is Ac-LKKTETQ (active fragment of 43-aa Tβ4). Common synonyms in the literature include Thymosin Beta 4, Tβ4, and TB4.

What it's studied for

Investigation of TB-500 (Thymosin Beta-4 Fragment) to date is clinical-investigational, with the majority of citations concentrated in animal models and in-vitro assays rather than randomized controlled human trials. Published work referencing TB-500 (Thymosin Beta-4 Fragment) spans Dermal wound healing models: Phase 2 human trials for stasis and pressure ulcers showed accelerated healing by almost a month in responding patients. Day 4 topical application showed 42% improvement in reepithelialization vs. saline controls, increasing to 61% by day 7. Animal studies demonstrated thicker collagen fiber bundles with reduced wound width and scarring, Cardiac injury research: Human clinical trials explored TB-4's ability to protect and repair cardiac tissue following acute myocardial infarction. In one trial, endothelial progenitor cells combined with TB-4 were transplanted into post-MI patients, showing improved walk time and cardiac function after 6 months. Animal studies indicate TB-4 helps repair heart damage and improves cardiac vasculature, and Musculoskeletal models: Rodent studies have examined TB-500 in muscle injury, tendon healing, and ligament repair contexts. Observations include effects on fibroblast activity, collagen organization, and biomechanical recovery metrics. Proposed mechanisms in the literature include G-actin sequestration: binds G-actin 1:1, inhibits F-actin polymerization, modulates actin structures in hypoxic cardiac cells and ROCK1/MRTFA pathway: decreases ROCK1 protein, reduces profibrotic signaling via MRTFA/SRF in cardiac cells under hypoxia. None of this material describes therapeutic outcomes in humans, and BioInfinity does not sell, market, or provide dosing guidance for TB-500 (Thymosin Beta-4 Fragment) outside laboratory research.

Laboratory handling — storage and reconstitution

Lyophilized TB-500 (Thymosin Beta-4 Fragment) arrives as a fluffy off-white solid inside a sealed sterile vial. Because it ships as a lyophilized peptide (4963 Da (full Tβ4) / ~900 Da (TB-500 fragment) Da), the powder is best stored between 2–8 °C prior to reconstitution and returned to −20 °C in aliquots for long-term storage post-reconstitution. Reconstitution is typically performed with bacteriostatic water (0.9 % benzyl alcohol preserved) rather than sterile water because the preservative extends solution stability once the vial has been punctured. Warming the reconstituted solution to room temperature before drawing helps redissolve any peptide that has settled against the vial wall. Avoid repeated freeze–thaw cycles: for peptides in this molecular-weight range (4963 Da (full Tβ4) / ~900 Da (TB-500 fragment) Da), freeze–thaw stress is one of the most common causes of loss-of-purity between batches.

How this batch is verified

Every batch of TB-500 (Thymosin Beta-4 Fragment) ships with a batch-specific Certificate of Analysis produced by an ISO-accredited third-party analytical laboratory. Reversed-phase HPLC confirms the assay against the expected 4963 Da (full Tβ4) / ~900 Da (TB-500 fragment) Da mass (C212H350N56O78S (full Tβ4)); mass spectrometry validates the exact monoisotopic mass; endotoxin (LAL) testing confirms bacterial-contamination limits appropriate for laboratory research; and residual-solvent panels confirm the manufacturing pipeline. The lot number on the outer label matches the COA on the public /coa-library page — every purity claim is independently verifiable before you open the vial.

Related research

For the full mechanistic profile, published references, and constraint notes on TB-500 (Thymosin Beta-4 Fragment), see the TB-500 (Thymosin Beta-4 Fragment) research page. All references cited on that page are peer-reviewed primary literature.

Research use only. TB-500 is sold strictly for in-vitro and animal research. It is not a drug, food, supplement, or cosmetic and is not intended for human or veterinary consumption. No statements on this page describe or imply any therapeutic effect.

Technical Specifications

Molecular Formula: C212H350N56O78S
Molecular Weight: 4963.5 g/mol
Sequence: Ac-Ser-Asp-Lys-Pro-Asp-Met-Ala-Glu-Ile-Glu-Lys-Phe-Asp-Lys-Ser-Lys-Leu-Lys-Lys-Thr-Glu-Thr-Gln-Glu-Lys-Asn-Pro-Leu-Pro-Ser-Lys-Glu-Thr-Ile-Glu-Gln-Glu-Lys-Gln-Ala-Gly-Glu-Ser

About TB-500

TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring 43-amino acid peptide found in high concentrations in blood platelets, wound fluid, and other tissues. Thymosin Beta-4 was originally isolated from thymus extracts in the 1960s and has since been identified as a major actin-sequestering protein with significant roles in cell migration, differentiation, and cellular pathway. TB-500 represents a truncated, active region of the full Thymosin Beta-4 molecule, making it more practical for research applications while retaining the key biological activity associated with the parent molecule.

Mechanism of Action

TB-500's biological effects stem from several well-characterized mechanisms that have been studied extensively in laboratory and preclinical settings:

Actin Sequestration: TB-500's primary function involves binding to G-actin (monomeric actin), preventing its polymerization into F-actin filaments. This regulation of actin dynamics is crucial for cell motility and morphological changes during cellular pathway.

Cell Migration Promotion: By modulating the actin cytoskeleton, TB-500 promotes cell migration—a critical process in wound-model research, angiogenesis, and cellular-pathway research. Research shows enhanced migration of endothelial cells, keratinocytes, and other cell types.

Angiogenesis Stimulation: Studies demonstrate TB-500's ability to promote new blood vessel formation. This involves upregulation of VEGF and other angiogenic factors, along with direct effects on endothelial cell proliferation and migration.

Inflammatory Pathway Research: Research indicates TB-500 may modulate cytokine expression and inflammatory cell activity in laboratory studies. Studies show altered expression of inflammatory markers in various experimental models.

Stem Cell Recruitment: Some research suggests TB-500 may influence the mobilization and differentiation of stem and progenitor cells, potentially contributing to its observed cellular-pathway effects.

Research Highlights

Cardiac Research

TB-500/Thymosin Beta-4 has been extensively studied in cardiac research. Studies in animal models of myocardial infarction have shown reduced scar formation, improved cardiac function, and enhanced survival of cardiomyocytes. Clinical trials have explored its potential in cardiac cellular-pathway research following heart attack.

Corneal Healing Studies

Significant research has focused on TB-500's effects on corneal healing. Studies demonstrate accelerated corneal wound closure, reduced inflammation, and improved outcomes in various corneal injury models. This research led to clinical development of Thymosin Beta-4-based eye drops.

Dermal Cellular Research

Research has examined TB-500's effects on skin wounds, including burns, incisions, and chronic wounds. Studies report accelerated wound closure, enhanced epithelialization, improved collagen organization, and reduced scarring in various experimental models.

Musculoskeletal Research

Preclinical studies have investigated TB-500's effects on muscle, tendon, and ligament injuries. Research shows potential benefits for muscle strain recovery, tendon healing, and joint health, with observations of reduced inflammation and accelerated cellular pathway.

Product Specifications

Molecular Formula	C₂₁₂H₃₅₀N₅₆O₇₈S
Molecular Weight	4963.44 g/mol
Sequence	Ac-SDKPDMAEIIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES (43 AA)
Purity	≥99% (HPLC verified)
Form	Lyophilized powder
Appearance	White to off-white powder
Solubility	Soluble in water, bacteriostatic water
Storage	2–8°C refrigerated (normal). Long-term: −20°C lyophilized.

Research Usage Guidelines

Reconstitution Protocol

1Allow vial to reach room temperature before reconstitution
2Use bacteriostatic water for multi-use applications
3Add solvent gently down the inside wall of the vial
4Allow to dissolve naturally or gently swirl—never shake
5Typical reconstitution: 2mL per 5mg vial yields 2.5mg/mL concentration

Storage Guidelines

•Lyophilized TB-500 (normal): Refrigerate at 2–8°C
•Lyophilized TB-500 (long-term, until expiry): Store at −20°C for optimal stability
•Reconstituted: Refrigerate at 2–8°C, stable for 2–3 weeks
•Protect from light exposure
•Avoid multiple freeze-thaw cycles—aliquot for long-term storage

Frequently Asked Questions

TB-500 is a synthetic peptide based on Thymosin Beta-4, a naturally occurring protein involved in cell migration and cellular pathway research. It consists of 43 amino acids and has been studied for its potential healing and cellular-pathway properties.

Research References

[1] Goldstein AL, et al. Thymosin beta4: a multi-functional structural peptide. Expert Opin Biol Ther. 2012;12(suppl 1):S37-S51.
[2] Sosne G, et al. Thymosin beta 4 promotes corneal wound-model research and decreases inflammation in vivo following alkali injury. Exp Eye Res. 2002;74(2):293-299.
[3] Bock-Marquette I, et al. Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair. Nature. 2004;432(7016):466-472.
[4] Hinkel R, et al. Thymosin beta4: a key factor for protective effects of eEPCs in acute and chronic ischemia. Ann N Y Acad Sci. 2010;1194:105-111.

Learn More

Explore our comprehensive research guides for detailed information on peptide handling, storage, and research protocols.

Reconstitution Guide →Storage Guide →COA Guide →

Customer Reviews

Verified research purchases

5.0(7 reviews)

Mike T.Verified

2 weeks ago

Finally found a quality source

Been searching for a reliable supplier for months. The purity is legit - you can verify it yourself on the lab's website. Shipped fast and arrived cold. Will definitely reorder.

47 people found this helpful

Sarah K.Verified

1 month ago

Third order - never disappointed

This is my go-to source now. Consistent quality every time, and the customer service actually responds when you have questions. The quantity discounts are a nice bonus too.

32 people found this helpful

Jason R.Verified

3 weeks ago

Best I've tried

After trying 3 different suppliers, this one stands out. The COA is verifiable, shipping is fast, and the product quality speaks for itself. Highly recommend.

28 people found this helpful

James W.Verified

2 months ago

Same-day shipping is clutch

Ordered before 2PM and it shipped the same day. Package arrived in perfect condition with ice packs still frozen. That's how it should be done.

41 people found this helpful

Chris M.Verified

1 week ago

Worth every penny

You get what you pay for. The third-party testing and COA verification gives me confidence. Already placed my second order.

56 people found this helpful

Patricia L.Verified

6 weeks ago

Transparency is refreshing

Love that I can verify the COA directly on Verum's website. The full analytical report with HPLC chromatogram checked out. This level of transparency is rare.

23 people found this helpful

David H.Verified

1 month ago

Professional from start to finish

Proper packaging, cold shipping, and everything documented. You can tell they take quality seriously. Already recommended to friends.

19 people found this helpful

Frequently Researched Together

Commonly studied alongside in laboratory settings

Bundle total (3 items):$147.00

Research FAQ — TB-500

Frequently asked questions about this compound for laboratory researchers.

What is TB-500 and how is it studied?+

TB-500 is a synthetic fragment corresponding to amino acids 17–23 of the native protein Thymosin Beta-4. Published research investigates its role in actin sequestration, angiogenesis modulation, and migration of progenitor cells in tissue-injury models.

Cited: PMID 17192546, PMID 22737108

What concentrations are used in TB-500 research?+

Rodent and large-animal research papers cite a wide range, often 1–10 mg/kg administered intraperitoneally or subcutaneously. Researchers should follow their IRB protocol and the dosing reported in the cited literature.

Cited: PMID 22737108

How is TB-500 different from full-length Thymosin Beta-4?+

TB-500 represents an active fragment of the full 43-amino-acid Thymosin Beta-4 protein. Research suggests the fragment retains the actin-binding region thought to mediate several of TB-4's reported effects.

Cited: PMID 17192546

How should TB-500 be reconstituted and stored?+

Lyophilized TB-500 is typically reconstituted with bacteriostatic water at 1–5 mg/mL and stored at 2–8 °C after reconstitution. Lyophilized vials store at −20 °C. Refer to your laboratory's SOP and product COA.

Published research references

Peer-reviewed literature relevant to TB-500 research. Linked PubMed IDs open the original source.

[1]Thymosin beta 4 and cardiac protection: implication in inflammation and fibrosis — Ann N Y Acad Sci (2012) · PMID 22737108
[2]Thymosin beta-4: a multi-functional regenerative peptide — Expert Opin Biol Ther (2007) · PMID 17192546
[3]Thymosin beta-4 and the anti-fibrotic effects on the heart — Ann N Y Acad Sci (2010) · PMID 21564349

Reviewed by the BioInfinity Research Team

Content reviewed by our research and quality team — biochemistry-degreed reviewers working alongside our analytical lab partner (Janoshik Analytical). Every product page is cross-checked against the cited peer-reviewed literature and the current batch's third-party COA.

For laboratory research use only. Not for human or veterinary use. Content is informational and does not constitute medical advice.

Verified reviews — TB-500

1 verified buyer

★★★★★

5.0 / 5

thesaintnoahVerified buyer

Jun 8, 2026

★★★★★

Exceptional fast shipping and Customer Service

Amazing product, BioInfinity is the only place i am going to use in the future, thanks for the amazing customer service you are providing!

Reviews are submitted by verified buyers via per-order tokenized links. Reviews are evaluated for product-focused content; any review containing therapeutic claims (cured, treats, healed, etc.) may be edited or hidden to maintain compliance with FDA and platform guidelines.

Learn More About This Peptide

TB-500 Research Summary →Browse All Peptide Research →Research Guides & Protocols

Research Use Only: This product is intended for laboratory research purposes only. Not for human consumption.

Research summary

TB-500 (Thymosin Beta-4 Fragment) — clinical & mechanistic profile

TB-500 is a synthetic 7-amino-acid fragment from thymosin beta-4's actin-binding site. A Phase 1/2 trial launched February 2026 investigates its cardiovascular effects in adults with stable atherosclerotic disease. Phase 1 safety data in 84 healthy volunteers showed favorable tolerability. 2025 research reveals its wound-healing activity may stem from the metabolite Ac-LKKTE rather than the parent compound.

Research status

clinical investigational

Sequence

Ac-LKKTETQ (active fragment of 43-aa Tβ4)

Molecular weight

4963 Da (full Tβ4) / ~900 Da (TB-500 fragment)

Molecular formula

C212H350N56O78S (full Tβ4)

Studied applications

•G-actin sequestration: forms 1:1 complex with G-actin, preventing F-actin assembly, modulating cytoskeletal dynamics for cell migration
•ROCK1 downregulation: decreases ROCK1 protein levels particularly under hypoxia, reducing profibrotic signaling via MRTFA/SRF pathways
•Wound healing: Phase 2 trials show 42% improvement in reepithelialization by day 4, 61% by day 7; thicker collagen, reduced scarring
•Cardiac protection: post-MI trials with EPC transplantation showed improved walk time and cardiac function at 6 months; activates epicardial progenitors
•Progenitor mobilization: enhances stem cell recruitment and differentiation; reactivates embryonic gene programs in cardiac tissue

Mechanisms of action

•G-actin sequestration: binds G-actin 1:1, inhibits F-actin polymerization, modulates actin structures in hypoxic cardiac cells
•ROCK1/MRTFA pathway: decreases ROCK1 protein, reduces profibrotic signaling via MRTFA/SRF in cardiac cells under hypoxia
•Cell migration promotion: alters cytoskeletal dynamics to enhance fibroblast, stem cell, and progenitor movement to injury sites
•Angiogenesis induction: promotes new vessel formation via endothelial proliferation; increases capillary density and capsulin+ progenitors
•Anti-inflammatory/anti-fibrotic: reduces myofibroblast accumulation, modulates inflammatory markers, decreases scarring potential
•Epicardial activation: reactivates embryonic gene programs, epicardial thickening, Wnt pathway modulation in cardiac models

Research constraints & safety notes

•Not approved by FDA or any regulatory agency for human therapeutic use
•Prohibited by WADA under S0 category (Non-Approved Substances) for athletic use
•Human clinical data limited to Phase 2 trials for specific wound types
•Most evidence derives from animal models rather than human subjects
•Long-term safety data in humans is not established

Peer-reviewed references

Goldstein AL, et al. — Thymosin beta-4 in wound repair (2008)PMID: 18492738View
Bock-Marquette I, et al. — Cardiac repair mechanismsPMID: 22431019View
Phase 2 clinical trial results for pressure/stasis ulcersPMID: 23050815View
Sosne G, et al. — TB4 in corneal wound healingPMID: 16923388View
Smart N, et al. — Cardiac progenitor cell activationPMID: 17641392View

Read the full TB-500 (Thymosin Beta-4 Fragment) research page View public COA library

For research use only. This summary is a research-scientific overview compiled from peer-reviewed sources. It is not medical advice and is not intended for human or veterinary consumption.

Researchers looking at this often also study

Full catalog

Includes this compound

BPC-157 & TB-500 Blend

View product

Includes this compound

Glow Blend

View product

Same research area — muscle-performance

5-Amino-1MQ

View product

Same research area — tissue-repair research

BPC-157

View product